Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 8/20 | 0.44 |
| ▸ | HPGD | P15428 | 6/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.44 |
| ▸ | MAPT | P10636 | 5/20 | 0.44 |
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | POLB | P06746 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.43 |
| ▸ | USP2 | O75604 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21533749 | 0.88 | MEN1 (0.42) | MEN1KMT2ATDP1NPC1HPGD | |
| SCHEMBL21533666 | 0.83 | KDM4E (0.47) | MEN1KMT2ANPC1KDM4EPOLB | |
| SCHEMBL21533705 | 0.82 | CDYL (0.46) | MEN1KMT2ATDP1NPC1HPGD | |
| SCHEMBL21171729 | 0.80 | MAOB (0.51) | MEN1KMT2ANPC1HPGDKDM4E | |
| SCHEMBL24818340 | 0.80 | ALDH1A1 (0.44) | MEN1KMT2ATDP1NPC1HPGD | |
| SCHEMBL21533688 | 0.78 | KMT2A (0.45) | MEN1KMT2ATDP1NPC1HPGD | |
| SCHEMBL21171898 | 0.78 | NPC1 (0.48) | TDP1NPC1HPGDMAPTSMN1; SMN2 | |
| SCHEMBL24486829 | 0.78 | XDH (0.48) | TDP1KDM4EPOLBCYP1A2CYP3A4 | |
| SCHEMBL24637668 | 0.77 | HPGD (0.48) | MEN1KMT2ATDP1NPC1HPGD | |
| SCHEMBL24486825 | 0.76 | CYP2D6 (0.58) | TDP1HPGDKDM4ELMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220412963-A1 | FLUORESCENCE TAGGING OF GLYCANS AND OTHER BIOMOLECULES THROUGH REDUCTIVE AMINATION FOR ENHANCED MS SIGNALS | WATERS TECHNOLOGIES CORPORATION | 2022-12-29 | — | — | US | disclosed |
| US-11061023-B2 | Fluorescence tagging of glycans and other biomolecules through reductive amination for enhanced MS signals | WATERS TECHNOLOGIES CORPORATION (US) | 2021-07-13 | — | — | US | disclosed |
| US-20190331669-A1 | FLUORESCENCE TAGGING OF GLYCANS AND OTHER BIOMOLECULES THROUGH REDUCTIVE AMINATION FOR ENHANCED MS SIGNALS | WATERS TECHNOLOGIES CORPORATION (US) | 2019-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190331669-A1 | FLUORESCENCE TAGGING OF GLYCANS AND OTHER BIOMOLECULES THROUGH REDUCTIVE AMINATION FOR ENHANCED MS SIGNALS | FUT5, FUT6, OGT | MEN1 3289/4885KMT2A 2258/4885TDP1 4602/4885 |
| US-20220412963-A1 | FLUORESCENCE TAGGING OF GLYCANS AND OTHER BIOMOLECULES THROUGH REDUCTIVE AMINATION FOR ENHANCED MS SIGNALS | FUT5, FUT6, OGT | MEN1 3289/4885KMT2A 2258/4885TDP1 4602/4885 |
| US-11061023-B2 | Fluorescence tagging of glycans and other biomolecules through reductive amination for enhanced MS signals | FUT5, FUT6, OGT | MEN1 3289/4885KMT2A 2258/4885TDP1 4602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.